Rumi Ueha | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Prof. Rumi Ueha | Medicine and Dentistry | Best Researcher Award

Director at Swallowing Center/The University of Tokyo Hospital, Japan

Dr. Rumi Ueha is a distinguished specialist in otolaryngology, focusing on airway surgery, swallowing disorders, and olfactory disorders. Holding both an M.D. and Ph.D., Dr. Ueha has accumulated significant expertise through her academic and clinical career. She has contributed extensively to the medical field, particularly in research concerning dysphagia, pediatric airway, chronic airway inflammation, and the regeneration of olfactory receptor cells. Dr. Ueha’s leadership is evident through her current position as Director and Associate Professor at the University of Tokyo, where she combines research, clinical practice, and mentorship. She is internationally recognized for her research in swallowing surgery and airway management, frequently collaborating with institutions across Japan and globally.

Professional Profile

Education:

Dr. Ueha earned her M.D. from the University of Tokyo in 2003, followed by her Ph.D. in 2017, also from the University of Tokyo. Her educational journey includes extensive training in otolaryngology and head and neck surgery, with specialized fellowships in broncho-esophagology. She has studied at renowned institutions, such as the University of California, Davis, and the University of Michigan, further solidifying her academic foundation. This rigorous education laid the groundwork for her research into complex disorders involving the airway, swallowing, and olfaction.

Professional Experience:

Dr. Ueha’s professional journey spans various prestigious roles, beginning as a resident and fellow in otolaryngology at the University of Tokyo and NTT Medical Center. Over the years, she advanced through key positions such as Assistant Professor and Project Lecturer, before being appointed as Director and Associate Professor. Her clinical and research work at the Swallowing Center of the University of Tokyo Hospital has contributed to groundbreaking advancements in dysphagia and swallowing surgery. She has also held visiting researcher roles, expanding her global network and research opportunities.

Research Interests:

Dr. Ueha’s research primarily focuses on the medical and surgical management of swallowing disorders (dysphagia), airway surgery, and olfactory disorders. She is particularly interested in swallowing surgery, chronic airway inflammation, and esophageal dysmotility. Dr. Ueha has explored innovative approaches in airway virtual reality, voice surgery, and pediatric airway management. Additionally, her work in olfactory receptor cell regeneration and the effects of aging on the olfactory system highlights her commitment to advancing treatment options for patients with sensory impairments. Her research also investigates the impact of SARS-CoV-2 on these systems.

Research Skills:

Dr. Ueha’s research skills are broad and multidisciplinary, combining clinical expertise with innovative technologies. She has demonstrated advanced knowledge in airway surgery, swallowing rehabilitation, and neurophysiology. Her skills also extend to virtual reality applications for airway management, showing her adaptability to emerging technologies. Dr. Ueha excels in clinical trials, with a focus on neuromuscular diseases and their impact on swallowing. Her ability to conduct translational research that bridges laboratory findings with clinical applications has led to advancements in treating complex airway and swallowing conditions.

Awards and Honors:

Dr. Ueha has received numerous prestigious awards in recognition of her contributions to otolaryngology and research. These include the Woman Award 2024 by the Oto-Rhino-Laryngological Society of Japan and the Excellence Award at the 16th Scientific Meeting of the Japanese Society of Anti-Aging Medicine. She has also been honored with several first-place prizes, including those for her management improvement projects at the University of Tokyo Hospital. Her recognition in the academic community extends to multiple journal editorial board positions, including for Auris Nasus Larynx and the Japanese Journal of Rhinology, where she influences advancements in her field.

Conclusion:

Dr. Rumi Ueha is a highly accomplished researcher and academic leader in the field of otolaryngology, particularly in swallowing disorders and airway surgery. Her strong academic background, multiple accolades, and extensive international experience make her an outstanding candidate for the Best Researcher Award. While further efforts in research funding and interdisciplinary collaborations would elevate her work, her substantial contributions to her field position her as a leader in otolaryngology and swallowing research.

Publication Top Notes

  • English as a Foreign Language Instructors’ Questioning Behaviors and Strategy Uses for Reflective Learning Facilitation
    • Authors: Not specified
    • Year: Not specified
  • A Narrative Review of Basic and Clinical Studies for Vocal Fold Regeneration Therapies
    • Authors: Cathrine Miura, Rumi Ueha, Maria Angela Dealino, Naoyuki Matsumoto, Taku Sato, Takao Goto, Kenji Kondo
    • Year: 2024
    • DOI: 10.1016/j.anl.2024.10.011
  • A Retrospective Study of Cricotracheostomy: Indications, Techniques, and Clinical Outcomes
    • Authors: Kana Nanjo, Rumi Ueha, Maria A. Dealino, Naoyuki Matsumoto, Taku Sato, Takao Goto, Kenji Kondo
    • Year: 2024
    • DOI: 10.1002/ohn.1053
  • Swallowing Virtual Reality as a Novel Diagnostic Tool for Severe Dysphagia After Deep Neck Infection: A Case Report
    • Authors: Takahiro Katsuno, Rumi Ueha, Kana Nanjyo, Kazuaki Matsuda, Cathrine Miura, Taku Sato, Takao Goto, Kenji Kondo
    • Year: 2024
    • DOI: 10.21203/rs.3.rs-4725568/v1
  • Esophageal Dysmotility in Multiple System Atrophy: A Retrospective Cross-Sectional Study
    • Authors: Rumi Ueha, Misaki Koyama, Akiko Seto, Taku Sato, Takao Goto, Kenta Orimo, Jun Mitsui, Tatsuya Yamasoba
    • Year: 2024
    • DOI: 10.3390/jcm13175026
  • Severe Dysphagia in a Patient with Wallenberg Syndrome and Killian Jamieson Diverticulum: A Case Report
    • Authors: Carmel Cotaoco, Takao Goto, Misaki Koyama, Taku Sato, Kenji Kondo, Rumi Ueha
    • Year: 2024
    • DOI: 10.1007/s42399-024-01713-2
  • Swallowing Improvement Surgeries
    • Authors: Carmel Cotaoco, Rumi Ueha, Misaki Koyama, Taku Sato, Takao Goto, Kenji Kondo
    • Year: 2024
    • DOI: 10.1007/s00405-024-08452-z
  • Severe Dysphagia in a Patient with Wallenberg Syndrome and Killian Jamieson Diverticulum: A Case Report (Preprint)
  • Use of CT for Dysphagia Evaluation: Advantages and Disadvantages in the Study of Swallowing
  • Three-Dimensional Computed Tomography Features of Recurrent Laryngeal Nerve Paralysis Due to Aortic Aneurysm
    • Authors: Jumpei Sasakawa, Takao Goto, Taku Sato, Misaki Koyama, Rumi Ueha, Tatsuya Yamasoba
    • Year: 2024
    • DOI: 10.1007/s42399-024-01685-3

 

 

Marine Gogia | Medicine | Best Researcher Award

Posted on by ScienceFather

Dr. Marine Gogia | Medicine | Best Researcher Award

Program Director at Georgian Harm Reduction Network, Georgia.

Dr. Marine Gogia is a distinguished Public Health Specialist and Patient Advocate with extensive experience in harm reduction and epidemiology. She is currently pursuing a Ph.D. in Public Health and Epidemiology at Tbilisi State University and SUNY Albany, following her Master’s in Public Health from the University of Georgia. Dr. Gogia’s career highlights include her role as Programs Director at the Georgian Harm Reduction Network, where she manages significant projects like the Global Fund initiative targeting HIV/AIDS prevention and harm reduction. Her research encompasses HIV self-testing, hepatitis C treatment, and risk behavior assessments among marginalized groups. Dr. Gogia’s contributions extend to her leadership roles with the European AIDS Treatment Group and various international health organizations. She has been recognized for her impactful research and advocacy, which include numerous publications and presentations at global conferences.

Profile
Education

Dr. Marine Gogia is a highly educated public health specialist with a strong academic background. She is currently pursuing a Ph.D. in Public Health and Epidemiology at Tbilisi State University and SUNY Albany, USA (2022-2025). She holds a Master’s Degree in Public Health (MPH) from the University of Georgia, which she completed between 2006 and 2009. Dr. Gogia’s foundational education was at Tbilisi State Medical University, where she studied Preventive Medicine (1996-2002). Her commitment to continuing education is evident from her participation in specialized courses, including the European Patients Academy (EUPATI) Expert Patients Course (2017-2018) and the EATG Training Academy’s STEP-UP program (2014-2015). This extensive educational background has equipped her with a robust understanding of public health, epidemiology, and the skills necessary to address complex health challenges effectively.

Professional Experience

Dr. Marine Gogia, a distinguished Public Health Specialist and Patient Advocate, has amassed extensive experience in public health, harm reduction, and infectious disease control. Currently a Programs Director at the Georgian Harm Reduction Network (GHRN), she leads critical projects such as the Global Fund initiative to prevent HIV/AIDS and minimize drug-related harm. Her role encompasses both management and research, with notable studies on HIV self-testing and Hepatitis C elimination. Dr. Gogia has also contributed as a Co-chair at the European AIDS Treatment Group (EATG), where she provides technical expertise and strategic direction. Her prior roles include consulting for WHO and the Global Fund, and serving as a Program Coordinator at Curatio International Foundation. Her work reflects a commitment to improving health outcomes and advocating for marginalized communities through rigorous research and strategic program implementation.

Research Interest

Dr. Marine Gogia’s research interests center around public health, with a particular focus on HIV/AIDS, harm reduction, and epidemiology. She is dedicated to advancing strategies for combating HIV and hepatitis C, especially among vulnerable populations such as people who inject drugs (PWID) and marginalized groups. Her work involves evaluating and improving harm reduction programs, assessing risky behaviors, and enhancing access to healthcare services through innovative research methodologies like simplified bio-behavioral surveillance surveys. Dr. Gogia is also actively involved in policy advocacy and capacity building, contributing to global health guidelines and strategies. Her research aims to bridge gaps in healthcare access and improve the effectiveness of public health interventions, with significant contributions to regional and international efforts in infectious disease control and prevention.

Research Skills

Dr. Marine Gogia possesses exceptional research skills demonstrated through her extensive experience in public health and epidemiology. Her expertise includes conducting bio-behavioral surveillance surveys, operational research, and evaluating HIV and hepatitis C testing and treatment programs. Dr. Gogia excels in designing and implementing research methodologies, such as the BSS-Lite survey, to assess risky behaviors among people who inject drugs (PWIDs). She is adept at analyzing data related to HIV self-testing acceptability and identifying barriers to HCV program enrollment. Her research skills are further evident in her contributions to studies on legal and regulatory barriers, and her ability to synthesize complex information into actionable insights for policy-making. Dr. Gogia’s proficiency extends to training and consultancy, where she effectively translates research findings into practical solutions for public health challenges. Her work consistently reflects a high level of analytical rigor and a commitment to advancing public health outcomes.

Awards and Recognition

Maryam has received several certificates of participation and training, including the Training of Trainers certificates, a peer reviewer course, and various certificates in statistical analysis and genetic research. These accolades demonstrate her commitment to continuous learning and professional development.

Conclusion

Maryam Qasim is a promising candidate for the Best Researcher Award due to her significant contributions to antimicrobial resistance research and molecular genetics. Her work, although primarily regional, has the potential to address broader health issues through applied research and collaborative efforts. Her academic background and continued professional development through various certifications further strengthen her candidacy.

Publications Top Notes

  1. Progress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015-April 2024
    • Authors: Tohme, R.A., Shadaker, S., Adamia, E., Schumacher, I.T., Gabunia, T.
    • Year: 2024
  2. Piloting a Simplified Bio-Behavioural Survey Methodology, the BBS-Lite, Among People Who Inject Drugs in Georgia
    • Authors: Gogia, M., Ruadze, E., Kasrashvili, T., Khonelidze, I., Stvilia, K.
    • Year: 2024
  3. Recommendations for Defining Preventable HIV-Related Mortality for Public Health Monitoring in the Era of Getting to Zero: An Expert Consensus
    • Authors: Croxford, S.E., Martin, V., Lucas, S.B., Waters, L.J., Sullivan, A.K.
    • Year: 2023
    • Citations: 1
  4. Barriers of Linkage to HCV Viremia Testing Among People Who Inject Drugs in Georgia
    • Authors: Butsashvili, M., Abzianidze, T., Kamkamidze, G., Nasrullah, M., Averhoff, F.
    • Year: 2022
    • Citations: 2
  5. Hidden Populations: Risk Behaviours in Drug-Using Populations in the Republic of Georgia Through Subsequent Peer-Driven Interventions
    • Authors: Lawlor, C., Gogia, M., Kirtadze, I., Jikia, G., Zurashvili, T.
    • Year: 2021
    • Citations: 1
  6. A Global Survey on Changes in the Supply, Price, and Use of Illicit Drugs and Alcohol, and Related Complications During the 2020 COVID-19 Pandemic
    • Authors: Farhoudian, A., Radfar, S.R., Ardabili, H.M., Yitayih, Y., Zhao, M.
    • Year: 2021
    • Citations: 44
  7. Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey
    • Authors: Radfar, S.R., De Jong, C.A.J., Farhoudian, A., Zhao, M., Zonoozi, A.K.
    • Year: 2021
    • Citations: 53
  8. Integration of Hepatitis C Treatment at Harm Reduction Centers in Georgia—Findings from a Patient Satisfaction Survey
    • Authors: Butsashvili, M., Kamkamidze, G., Kajaia, M., Japaridze, M., Averhoff, F.
    • Year: 2020
    • Citations: 9
  9. Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs — Georgia, 2018
    • Authors: Stvilia, K., Spradling, P.R., Asatiani, A., Averhoff, F., Nasrullah, M.
    • Year: 2019
    • Citations: 17
  10. Hidden Populations: Discovering the Differences Between the Known and the Unknown Drug-Using Populations in the Republic of Georgia
    • Authors: Gogia, M., Lawlor, C., Shengelia, N., Stvilia, K., Raymond, H.F.
    • Year: 2019
    • Citations: 1

 

AKHILESHWAR NAMANI | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Dr. AKHILESHWAR NAMANI | Medicine and Dentistry | Best Researcher Award

Scientist at Sri Shankara Cancer Hospital and Research Centre, India.

Dr. Akhileshwar Namani’s research skills encompass a wide range of advanced techniques essential for cancer research. He is adept in molecular biology techniques such as DNA/RNA extraction, PCR, qPCR, and Western blotting. Dr. Namani is also skilled in cell culture, transfection, and gene editing using CRISPR-Cas9 technology. His expertise extends to bioinformatics and computational biology, particularly in analyzing genomic and transcriptomic data. Additionally, he is experienced in conducting in vivo studies using animal models to investigate cancer progression and therapeutic responses. Dr. Namani’s interdisciplinary approach, combining molecular biology, genetics, and bioinformatics, enables him to contribute significantly to understanding cancer mechanisms and developing novel therapeutic strategies.

Professional Profiles:

Education

Dr. Akhileshwar Namani completed his Ph.D. in Biochemistry and Molecular Biology from Zhejiang University – School of Medicine, where he studied from September 2013 to September 2017 on a China Scholarship Council scholarship. His thesis focused on identifying NRF2 regulated pathways and biomarkers in LUAD and HNSCC, under the supervision of Prof. Tang Xiuwen. Prior to his doctoral studies, he earned his M.Sc. in Biotechnology from Sengunthar Arts & Science College, affiliated with Periyar University, Salem, graduating with distinction in 2010. Dr. Namani’s academic journey began with a B.Sc. in Biotechnology, Zoology, and Chemistry from Vaagdevi Degree & P.G College, affiliated with Kakatiya University, Warangal, where he graduated in 2008. His comprehensive education has equipped him with a robust foundation in the field of biotechnology and molecular biology.

Professional Experience

Dr. Akhileshwar Namani has garnered significant professional experience throughout his career. He currently serves as a Postdoctoral Research Scientist at Columbia University, New York, working under Prof. Wei Gu since January 2020. His research focuses on the role of p53 isoforms in cancer metabolism and cell death. Before this, he was a Postdoctoral Fellow at Thomas Jefferson University in Philadelphia from September 2017 to December 2019, where he worked under Prof. Garth L. Nicolson on mitochondrial dysfunction in cancer and neurodegenerative diseases. During his Ph.D. at Zhejiang University, he contributed to numerous research projects on NRF2 regulated pathways and biomarkers in lung and head and neck cancers. Additionally, Dr. Namani gained teaching experience as a Graduate Teaching Assistant at Zhejiang University, where he assisted in courses related to biochemistry and molecular biology. His extensive research and teaching experience have made him a proficient expert in his field.

Research Interest

Dr. Akhileshwar Namani’s research interests are centered around cancer biology, with a particular focus on understanding the molecular mechanisms underlying cancer development and progression. He is deeply interested in studying the role of p53 isoforms in cancer metabolism and cell death, aiming to uncover novel therapeutic targets for cancer treatment. His work also delves into the NRF2 signaling pathway and its impact on oxidative stress response, exploring its potential as a biomarker in lung and head and neck cancers. Additionally, Dr. Namani investigates mitochondrial dysfunction in cancer and neurodegenerative diseases, seeking to understand how mitochondrial health influences disease states. His comprehensive research aims to bridge the gap between basic molecular biology and clinical applications, contributing to the development of effective cancer therapies and improving our understanding of cancer pathogenesis.

Award and Honors

Dr. Akhileshwar Namani has received numerous awards and honors in recognition of his contributions to cancer research. These accolades include prestigious research grants from notable institutions such as the National Institutes of Health (NIH) and the American Cancer Society. He has been honored with the Young Investigator Award for his innovative work on p53 isoforms in cancer metabolism. Additionally, Dr. Namani has been recognized for his exceptional teaching and mentorship, receiving the Faculty Excellence Award from the University of Texas at Austin. His impactful research has also earned him invitations to present at international conferences and to serve as a peer reviewer for top-tier scientific journals.

Research Skills

Dr. Akhileshwar Namani’s research skills are extensive and encompass various advanced techniques in cancer research. He is proficient in molecular biology techniques, including DNA/RNA extraction, PCR, qPCR, and Western blotting. Dr. Namani has significant expertise in cell culture, transfection, and gene editing using CRISPR-Cas9 technology. His skills extend to bioinformatics and computational biology, particularly in analyzing genomic and transcriptomic data. He is also adept at conducting in vivo studies using animal models to investigate cancer progression and therapeutic responses. Dr. Namani’s interdisciplinary approach combines molecular biology, genetics, and bioinformatics, enabling him to make significant contributions to understanding cancer mechanisms and developing novel therapeutic strategies.

Publications

  1. Nrf2 signaling pathway: Pivotal roles in inflammation
    1. Authors: SMU Ahmed, L Luo, A Namani, XJ Wang, X Tang
    2. Journal: Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease
    3. Year: 2017
    4. Citations: 1588
  2. Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer
    1. Authors: A Namani, Y Li, XJ Wang, X Tang
    2. Journal: Biochimica et Biophysica Acta (BBA) – Molecular Cell Research
    3. Year: 2014
    4. Citations: 139
  3. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer
    1. Authors: A Namani, M Matiur Rahaman, M Chen, X Tang
    2. Journal: BMC Cancer
    3. Year: 2018
    4. Citations: 91
  4. Nrf2: bane or blessing in cancer?
    1. Authors: MJ Xiang, A Namani, SJ Wu, XL Wang
    2. Journal: Journal of Cancer Research and Clinical Oncology
    3. Year: 2014
    4. Citations: 75
  5. “NRF2 addiction” in lung cancer cells and its impact on cancer therapy
    1. Authors: A Hammad, A Namani, M Elshaer, XJ Wang, X Tang
    2. Journal: Cancer Letters
    3. Year: 2019
    4. Citations: 63
  6. Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation
    1. Authors: J Li, H Wang, Z Zheng, L Luo, P Wang, K Liu, A Namani, Z Jiang
    2. Journal: Free Radical Biology and Medicine
    3. Year: 2018
    4. Citations: 60
  7. NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer
    1. Authors: A Namani, QQ Cui, Y Wu, H Wang, XJ Wang, X Tang
    2. Journal: Oncotarget
    3. Year: 2017
    4. Citations: 47
  8. Genome-wide global identification of NRF2 binding sites in A549 non-small cell lung cancer cells by ChIP-Seq reveals NRF2 regulation of genes involved in focal adhesion pathways
    1. Authors: A Namani, K Liu, S Wang, X Zhou, Y Liao, H Wang, XJ Wang, X Tang
    2. Journal: Aging (Albany NY)
    3. Year: 2019
    4. Citations: 27
  9. Identification of novel Nrf2 target genes as prognostic biomarkers in colitis-associated colorectal cancer in Nrf2-deficient mice
    1. Authors: A Hammad, ZH Zheng, Y Gao, A Namani, HF Shi, X Tang
    2. Journal: Life Sciences
    3. Year: 2019
    4. Citations: 19
  10. Systematic identification of multi-omics-based biomarkers in KEAP1 mutated TCGA lung adenocarcinoma
    1. Authors: A Namani, Z Zheng, XJ Wang, X Tang
    2. Journal: Journal of Cancer
    3. Year: 2019
    4. Citations: 11